Table 2 Aspirin use and risk of 5-year disease-specific mortality after esophagectomy for esophageal cancer (complete case analysis)

All patients

 No aspirin

657

225

1.00 (Reference)

1.00 (Reference)

 Aspirin

164

62

1.07 (0.81–1.42)

0.92 (0.67–1.28)

Age ≤ 59 years

 No aspirin

197

56

1.00 (Reference)

1.00 (Reference)

 Aspirin

23

8

0.95 (0.47–1.93)

1.04 (0.47–2.29)

Age 60–65 years

 No aspirin

154

57

1.00 (Reference)

1.00 (Reference)

 Aspirin

38

18

1.50 (0.93–2.43)

1.28 (0.72–2.27)

Age 66–71 years

 No aspirin

168

59

1.00 (Reference)

1.00 (Reference)

 Aspirin

61

20

0.88 (0.56–1.39)

0.78 (0.46–1.34)

Age ≥ 72 years

 No aspirin

138

53

1.00 (Reference)

1.00 (Reference)

 Aspirin

42

16

1.06 (0.64–1.77)

0.90 (0.50–1.63)

Men

 No aspirin

498

183

1.00 (Reference)

1.00 (Reference)

 Aspirin

147

59

1.15 (0.86–1.53)

0.99 (0.70–1.40)

Women

 No aspirin

159

42

1.00 (Reference)

1.00 (Reference)

 Aspirin

17

3

0.44 (0.14–1.37)

0.62 (0.19–2.02)

Tumor stage 0-I

 No aspirin

275

58

1.00 (Reference)

1.00 (Reference)

 Aspirin

66

12

0.44 (0.25–0.79)

0.78 (0.41–1.48)

Tumor stage II

 No aspirin

142

45

1.00 (Reference)

1.00 (Reference)

 Aspirin

40

18

1.28 (0.79–2.07)

1.30 (0.73–2.33)

Tumor stage III

 No aspirin

182

91

1.00 (Reference)

1.00 (Reference)

 Aspirin

46

25

1.92 (1.27–2.90)

0.98 (0.60–1.61)

Tumor stage IV

 No aspirin

58

31

1.00 (Reference)

1.00 (Reference)

 Aspirin

12

7

1.77 (0.83–3.75)

0.70 (0.30–1.62)

Adenocarcinoma histology

 No aspirin

488

160

1.00 (Reference)

1.00 (Reference)

 Aspirin

129

45

0.97 (0.70–1.33)

0.98 (0.67–1.144)

Squamous cell carcinoma histology

 No aspirin

169

65

1.00 (Reference)

1.00 (Reference)

 Aspirin

35

17

1.47 (0.90–2.40)

0.88 (0.50–1.57)